Adalimumab for Pediatric Sympathetic Ophthalmia

Sympathetic ophthalmia (SO) is an autoimmune, bilateral, granulomatous panuveitis occurring after accidental or surgical trauma to the eye.1 Systemic corticosteroids are first-line therapy for SO with immunomodulatory therapy employed for corticosteroid-sparing immunosuppression and chronic, refractory cases. Biologic response modifiers (BRMs) are a class of therapeutics that target specific cytokines mediating inflammation, and TNF-α antagonist BRMs have shown promise for uveitis.2 Herein, we report the first use, to our knowledge, of adalimumab for refractory pediatric SO leading to resolution of inflammation.